Table 3.
Antibiotics prescribed for acute rhinosinusitis in ENT and primary care clinics.
| Total Unweighted Visits | Total Weighted Visits | Total Proportion, % | ENT, % | PCP, % | P Value | |
|---|---|---|---|---|---|---|
| Macrolides | 223 | 5,000,000 | 32.3 ± 3.8 | 20.7 6 5.9 | 32.7 6 3.9 | .11 |
| Penicillins | ||||||
| Amoxicillin | 134 | 2,400,000 | 15.5 ± 4.2 | 3.0 ± 2.3 | 15.9 ± 4.4 | .02 |
| Amoxicillin/clavulanic acid | 98 | 2,200,000 | 14.6 ± 2.8 | 18.4 ± 7.0 | 14.4 ± 2.8 | .59 |
| Quinolones | 130 | 2,900,000 | 19.8 ± 2.8 | 37.3 ± 9.8 | 19.2 ± 2.8 | .03 |
| Second/third-generation cephalosporins | 85 | 1,500,000 | 10.1 ± 1.6 | 18.0 ± 7.9 | 9.9 ± 1.6 | .20 |
| Miscellaneousa | 65 | 1,200,000 | 7.8 ± 1.6 | 26.5 ± 2.7 | 8.0 ± 1.6 | .27 |
| Total broad-spectrumb | 531 | 1,200,000 | 76.3 ± 5.0 | 94.3 ± 3.6 | 75.7 ± 5.1 | .01 |
Abbreviations: ENT, otolaryngology; PCP, primary care physician.
a
First-generation cephalosporins, trimetroprim-sulfamethozazole, lincomycins, and tetracyclines.
b
Beta-lactamase–inhibiting penicillins, second- to fourth-generation cephalosporins, quinolones, azithromycin, and clarithromycin were classified as broad-spectrum agents.